Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Press Releases
Syndax Pharmaceuticals, Inc.  
November 5, 2024

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile –

logo salamanca press

Salamanca Press

Local & Social